Traders Sell Shares of Gilead Sciences (GILD) on Strength (GILD)

Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading on Wednesday. $130.19 million flowed into the stock on the tick-up and $214.99 million flowed out of the stock on the tick-down, for a money net flow of $84.80 million out of the stock. Of all equities tracked, Gilead Sciences had the 17th highest net out-flow for the day. Gilead Sciences traded up $0.49 for the day and closed at $76.58

GILD has been the subject of several analyst reports. BMO Capital Markets reissued a “hold” rating and issued a $82.00 target price on shares of Gilead Sciences in a report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price for the company in a report on Wednesday, September 6th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $85.11.

The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The firm has a market capitalization of $99,119.69, a price-to-earnings ratio of 7.92, a PEG ratio of -1.27 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.75 EPS. research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.72%. Gilead Sciences’s dividend payout ratio is currently 23.69%.

In other news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the transaction, the executive vice president now directly owns 70,988 shares in the company, valued at approximately $5,298,544.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 494,999 shares of company stock valued at $37,404,139 over the last quarter. Corporate insiders own 1.30% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of GILD. Contrarius Investment Management Ltd lifted its position in Gilead Sciences by 2,630.1% in the first quarter. Contrarius Investment Management Ltd now owns 904,865 shares of the biopharmaceutical company’s stock worth $61,458,000 after buying an additional 871,721 shares during the last quarter. Heritage Trust Co bought a new stake in Gilead Sciences in the first quarter worth $3,589,000. Pitcairn Co. lifted its position in Gilead Sciences by 37.1% in the first quarter. Pitcairn Co. now owns 19,231 shares of the biopharmaceutical company’s stock worth $1,306,000 after buying an additional 5,207 shares during the last quarter. Bienville Capital Management LLC bought a new stake in Gilead Sciences in the first quarter worth $570,000. Finally, Norinchukin Bank The lifted its position in Gilead Sciences by 4.2% in the first quarter. Norinchukin Bank The now owns 174,400 shares of the biopharmaceutical company’s stock worth $11,845,000 after buying an additional 7,070 shares during the last quarter. Institutional investors own 76.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Traders Sell Shares of Gilead Sciences (GILD) on Strength (GILD)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/12/13/traders-sell-shares-of-gilead-sciences-gild-on-strength-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply